단백분해효소 억제제를 포함한 항레트로바이러스 병용 치료중인 HIV 감염 한국인에서 Atazanavir로 변경 후 지질 수치의 변화
Lipid Profile Changes after Switch to Atazanavir from other Protease Inhibitor-based Combined Antiretroviral Treatment in HIV-infected Korean
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.
Abstract
Dyslipidemia, one of the major disadvantages of use of protease inhibitor (PI), is a risk factor for cardiovascular disease in HIV-infected patients receiving antiretroviral treatment. Little is known about the effect of a switch from another PI to unboosted atazanavir (ATV) on the lipid profile. The aim of this study was to evaluate changes in the lipid profile after switching from another PI to either unboosted or boosted ATV in HIV-infected Koreans. We retrospectively collected data on the serum lipid profile at the time of the switch (week 0), and weeks 12 and 24 after the switch, as well as clinical characteristics at week 0 in a total of 27 patients. Triglyceride (TG) showed a significant decrease at weeks 12 and 24 in all patients (196 vs. 174 mg/dL, P=0.048and 196 vs. 150 mg/dL, P=0.021, respectively). However, these effects were only observed in the unboosted ATV group (N=14; 239 vs. 125 mg/dL, P=0.017 and 239vs. 87 mg/dL, P=0.021, respectively). For total cholesterol, only the unboosted ATV group at 24 weeks showed a significant decrease (184 vs. 158 mg/dL, P=0.031). No significant changes were observed in LDL- and HDL-cholesterol at weeks 12 and 24in both the unboosted and boosted ATV groups. These results suggest that changing to unboosted ATV from another PI may ameliorate high TG and total cholesterol in HIV-infected Koreans.
참고문헌 (20)
- Naggie S., "Protease inhibitor-based antiretroviral therapy in treatment-naive HIV-1-infected patients : the evidence behind the options", J Antimicrob Chemother, 65, pp.1094~1099 (2010)
- Friis-Møller N., "DAD study group. Cardiovascular disease risk factors in HIV patientsassociation with antiretroviral therapy. Results from the DAD study", AIDS, 17, pp.1179~1193 (2003)
- Barbaro G., "Highly active antiretroviral therapy-associated metabolic syndrome : pathogenesis and cardiovascular risk", Am J Ther, 13, pp.248~260 (2006)
- Malan DR., "Efficacy and safety of atazanavir, with or without ritonavir, as part of once-daily highly active antiretroviral therapy regimens in antiretroviral-naive patients", J Acquired Immune Defic Syn-dromes, 47, pp.161~167 (2008)
- Raja A., "Atazanavir sulphate", Nat Rev Drug Discov, 2, pp.857~858 (2003)
- Squires K., "Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV", Acquired Immune Defic Syndromes, 36, pp.1011~1019 (2004)
- Johnson M., "96-week comparison of once-daily atazanavir", ritonavir and twice-daily lopinavir, AIDS, pp.2006, 20[DOI]
- Gatell J., "SWAN Study Group. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen : the SWAN Study(AI424-097)48-week results", Clin Infect Dis, 44, pp.1484~1492 (2007)
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services" (2006)[URL]
- "Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services"[URL]
- Squires KE., "ARIES study team. Similar efficacy and tolerability of atazanavir compared with atazanavir", ritonavir, each with abacavir, lamivudine plus ritonavirboosted atazanavir in HIV-infected patients, pp.AIDS, 2010[DOI]
- Ghosn J., "Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavirboosted regimen", Antivir Ther, 15, pp.993~1002 (2010)
- Han SH., "Serum retinol-binding protein 4 correlates with obesity, insulin resistance, and dyslipidemia in HIV-infected subjects receiving highly active antiretroviral therapy", Metabolism, 58, pp.1523~1529 (2009)
- Friedewald WT., "Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge", Clin Chem, 18, pp.499~502 (1972)
- Möbius U., "Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia", J Acquired Immune Defic Syndr, 39, pp.174~180 (2005)
- Shafran S., "The effect of low‐dose ritonavir monotherapy on fasting serum lipid concentrations", HIV Med, 6, pp.421~425 (2005)
- Mallolas J., "ATAZIP Study Group. Efficacy and safety of switching from boosted lopinavir to boosted atazanavir in patients with virological suppression receiving a LPV", r-containing HAART : the ATAZIP study, 2009, pp.51, 29~36
- Molina JM., "CASTLE Study Team. Once-daily atazanavir", ritonavir compared with twicedaily lopinavir, J Acquired Immune Defic Syndr, pp.2010, 53[DOI]
- Ghosn J., "Unboosted atazanavir-based therapy maintains control of HIV type-1 replication as effectively as a ritonavirboosted regimen", Antivir Ther, 15, pp.993~1002 (2010)
- Sension M., "Improvement in lipid profiles in antiretroviral-experienced HIV-positive patients with hyperlipidemia after a switch to unboosted atazanavir", J Acquired Immune Defic Syndr, 51, pp.153~162 (2009)